Strs Ohio Has $33.29 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Strs Ohio decreased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 6.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 648,792 shares of the biopharmaceutical company’s stock after selling 41,079 shares during the period. Strs Ohio’s holdings in Bristol-Myers Squibb were worth $33,289,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. True Wealth Design LLC bought a new position in Bristol-Myers Squibb during the fourth quarter valued at about $26,000. Coppell Advisory Solutions Corp. bought a new position in Bristol-Myers Squibb during the fourth quarter valued at about $31,000. Coppell Advisory Solutions LLC bought a new position in Bristol-Myers Squibb during the second quarter valued at about $28,000. Live Oak Investment Partners bought a new position in Bristol-Myers Squibb during the fourth quarter valued at about $33,000. Finally, OFI Invest Asset Management bought a new position in Bristol-Myers Squibb during the third quarter valued at about $25,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 0.5 %

Shares of BMY opened at $48.51 on Tuesday. Bristol-Myers Squibb has a 12-month low of $47.58 and a 12-month high of $70.93. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $98.32 billion, a price-to-earnings ratio of 12.57, a P/E/G ratio of 1.78 and a beta of 0.39. The stock’s 50-day moving average price is $51.29 and its 200 day moving average price is $51.69.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. The company had revenue of $11.48 billion for the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The company’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the business earned $1.82 earnings per share. As a group, research analysts predict that Bristol-Myers Squibb will post 5.41 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 4.95%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is 62.18%.

Analyst Ratings Changes

Several equities analysts have weighed in on BMY shares. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the company from $68.00 to $60.00 in a report on Wednesday, January 3rd. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Finally, Wells Fargo & Company dropped their price objective on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $61.12.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.